CRL Stock Analysis: Buy, Sell, or Hold?
CRL - Charles River Laboratories International, Inc.
$291.45
1.45 (0.50%)
▲
5d:
+3.62%
30d:
+33.26%
90d:
+86.79%
WAIT
LOW Confidence
Analysis Updated: Aug 20, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When CRL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CRL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CRL shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$305.87
Based on 8.1% avg growth
INTRINSIC VALUE TODAY
$189.92
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRL is currently trading at $291.45, which is considered extended relative to its 30-day fair value range of $223.66 to $275.21. From a valuation perspective, the stock is trading at a premium (Forward PE: 23.0) compared to its historical average (16.4). At these levels, the market is pricing in 11.9% annual earnings growth.
Technical Outlook: Technically, CRL is in a strong uptrend. The price is approaching resistance at $299.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRL is in a strong uptrend. The price is approaching resistance at $299.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$223.66 -
$275.21
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.4%
All Signals
- BEARISH: Price extended above range (+5.9% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($281.00)
- BULLISH: Expecting earnings turnaround to 11.9% growth with -2.7% revenue growth
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$223.66 -
$275.21
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$260.82
Resistance Level
$299.32
Current Trend
Strong Uptrend
Technical data as of
Aug 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.97
Wall Street Target
$281.00
(-3.6%)
Revenue Growth (YoY)
-2.7%
Earnings Growth (YoY)
-17.3%
Profit Margin
-6.0%
Valuation Premium vs History
+11.9% premium
PE vs Historical
23.0 vs 16.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.9%
(market-implied from PE analysis)
1-Year Target
$326.13
(+12%)
2-Year Target
$364.94
(+25%)
3-Year Target
$408.37
(+40%)
3-Yr Target (if PE normalizes)
(PE: 23→16)
PE COMPRESSION
$291.52
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.0, Growth: 12.1%)
$410.39
(+41%)
Base:
(SPY PE: 20.1, Growth: 12.1%)
$358.51
(+23%)
Bear:
(PE: 16.4, Growth: 12.1%)
$292.96
(+1%)
Share & Embed Analysis
Last updated: August 21, 2026 8:53 AM ET
Data refreshes hourly during market hours. Next update: 9:53 AM
Data refreshes hourly during market hours. Next update: 9:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-03-30
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$631 | 41 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 43 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 40 SELL |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$331 | 38 SELL |
